(Total Views: 593)
Posted On: 07/05/2023 5:20:33 PM
Post# of 148905
Food for thought and perspective...There has been absolutely NO effort at all to support/protect the stock price (might suggest funding in the bag).
Partnership agreements are contingent on the FDA lifting the clinical hold.
We know NDA's have been signed...signaled many times on CC's.
We know 1500 plus human patients treated with LL have been studied....broken up in HIV,NASH and Oncology (mainly mTNBC).
We know there is enough positive clinical signals for ANY Pharma player to engage in discussions about a partnership.
We know that in 2015 NP...Cytodyn moved the incorporation from Colorado to Delaware...and the Delaware Chancery Court is well known to have laws in place that protect (their) corporations.
We know that "poison pill clause"...serves as a defence against hostile takeovers.
We know that "advance Notice bylaws requires the board to identify "threat" and respond accordingly...so that a hedge fund or competing Pharma Company cannot just swoop in and grab CYDY on the cheap.
We know that approval hinges on a thorough evaluation of the Molecules efficacy, safety profile, and cost effectiveness while drawing comparison to existing therapies.
We have been told by notable physicians... that what they have seen is "truly amazing"...Think Dr. Scott Hansen...Dr. Stephan Gluck.."incredible the early results of LL had on mTNBC patients" Dr Mazeen Noureddin "remarkable data about LL in NASH."
We know...If warrants were exercised...it would raise about $45.5 Million.
We know we were 1 of 4 out of hundreds at the NASH conference...that was singled out.
AND lastly Amarex/NSF...is a likely source of future funding.
The Silence...has a lot to say
Partnership agreements are contingent on the FDA lifting the clinical hold.
We know NDA's have been signed...signaled many times on CC's.
We know 1500 plus human patients treated with LL have been studied....broken up in HIV,NASH and Oncology (mainly mTNBC).
We know there is enough positive clinical signals for ANY Pharma player to engage in discussions about a partnership.
We know that in 2015 NP...Cytodyn moved the incorporation from Colorado to Delaware...and the Delaware Chancery Court is well known to have laws in place that protect (their) corporations.
We know that "poison pill clause"...serves as a defence against hostile takeovers.
We know that "advance Notice bylaws requires the board to identify "threat" and respond accordingly...so that a hedge fund or competing Pharma Company cannot just swoop in and grab CYDY on the cheap.
We know that approval hinges on a thorough evaluation of the Molecules efficacy, safety profile, and cost effectiveness while drawing comparison to existing therapies.
We have been told by notable physicians... that what they have seen is "truly amazing"...Think Dr. Scott Hansen...Dr. Stephan Gluck.."incredible the early results of LL had on mTNBC patients" Dr Mazeen Noureddin "remarkable data about LL in NASH."
We know...If warrants were exercised...it would raise about $45.5 Million.
We know we were 1 of 4 out of hundreds at the NASH conference...that was singled out.
AND lastly Amarex/NSF...is a likely source of future funding.
The Silence...has a lot to say
(13)
(0)Scroll down for more posts ▼
